NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019-Reference-Cited by-同舟云学术

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Published:2019-06 Issue:6 Volume:17 Page:650-661
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Zelenetz Andrew D.¹,Gordon Leo I.²,Abramson Jeremy S.³,Advani Ranjana H.⁴,Bartlett Nancy L.⁵,Caimi Paolo F.⁶,Chang Julie E.⁷,Chavez Julio C.⁸,Christian Beth⁹,Fayad Luis E.¹⁰,Glenn Martha J.¹¹,Habermann Thomas M.¹²,Lee Harris Nancy³,Hernandez-Ilizaliturri Francisco¹³,Kaminski Mark S.¹⁴,Kelsey Christopher R.¹⁵,Khan Nadia¹⁶,Krivacic Susan¹⁷,LaCasce Ann S.¹⁸,Mehta Amitkumar¹⁹,Nademanee Auayporn²⁰,Rabinovitch Rachel²¹,Reddy Nishitha²²,Reid Erin²³,Roberts Kenneth B.²⁴,Smith Stephen D.²⁵,Snyder Erin D.¹⁹,Swinnen Lode J.²⁶,Vose Julie M.²⁷,Dwyer Mary A.²⁸,Sundar Hema²⁸

Affiliation:

1. 1Memorial Sloan Kettering Cancer Center;

2. 2Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

3. 3Massachusetts General Hospital Cancer Center;

4. 4Stanford Cancer Institute;

5. 5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

6. 6Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

7. 7University of Wisconsin Carbone Cancer Center;

8. 8Moffitt Cancer Center;

9. 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

10. 10The University of Texas MD Anderson Cancer Center;

11. 11Huntsman Cancer Institute at the University of Utah;

12. 12Mayo Clinic Cancer Center;

13. 13Roswell Park Comprehensive Cancer Center;

14. 14University of Michigan Rogel Cancer Center;

15. 15Duke Cancer Institute;

16. 16Fox Chase Cancer Center;

17. 17Consultant;

18. 18Dana-Farber/Brigham and Women’s Cancer Center;

19. 19O’Neal Comprehensive Cancer Center at UAB;

20. 20City of Hope National Medical Center;

21. 21University of Colorado Cancer Center;

22. 22Vanderbilt-Ingram Cancer Center;

23. 23UC San Diego Moores Cancer Center;

24. 24Yale Cancer Center/Smilow Cancer Hospital;

25. 25University of Washington/Seattle Cancer Care Alliance;

26. 26The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

27. 27Fred & Pamela Buffett Cancer Center; and

28. 28National Comprehensive Cancer Network.

Abstract

Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience;Annals of Hematology;2024-01-22

2. Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study;BMC Cancer;2024-01-12

3. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01

4. An assessment model for efficacy of patients with relapsed or refractory diffuse large B-cell lymphoma following autologous CD19 chimeric antigen receptor T-cell therapy.;2023-12-14

5. Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells;International Immunopharmacology;2023-12